Assuntos
Embolização Terapêutica , Próstata , Prostatectomia , Hiperplasia Prostática , Urodinâmica , Humanos , Prostatectomia/métodos , Masculino , Próstata/irrigação sanguínea , Próstata/patologia , Embolização Terapêutica/métodos , Hiperplasia Prostática/cirurgia , Hiperplasia Prostática/terapia , Hiperplasia Prostática/complicações , Ensaios Clínicos Controlados Aleatórios como Assunto , Tamanho do ÓrgãoRESUMO
Lymphatic filarial (LF) parasites have been under anti-filarial drug pressure for more than half a century. Currently, annual mass drug administration (MDA) of diethylcarbamazine (DEC) or ivermectin in combination with albendazole (ALB) have been used globally to eliminate LF. Long-term chemotherapies exert significant pressure on the genetic structure of parasitic populations. We investigated the genetic variation among 210 Wuchereria bancrofti populations that were under three different chemotherapy strategies, namely MDA with DEC alone (group I, n = 74), MDA with DEC and ALB (group II, n = 60) and selective therapy (ST) with DEC (group III, n = 34) to understand the impact of these three drug regimens on the parasite genetic structure. Randomly amplified polymorphic DNA profiles were generated for the three groups of parasite populations; the gene diversity, gene flow and genetic distance values were determined and phylogenetic trees were constructed. Analysis of these parameters indicated that parasite populations under ST with a standard dose of DEC (group III) were genetically more diverse (0.2660) than parasite populations under MDA with DEC alone (group I, H = 0.2197) or with DEC + ALB (group II, H = 0.2317). These results indicate that the MDA may reduce the genetic diversity of W. bancrofti populations when compared to the genetic diversity of parasite populations under ST.
Assuntos
Albendazol/administração & dosagem , Dietilcarbamazina/administração & dosagem , Filaricidas/administração & dosagem , Variação Genética/efeitos dos fármacos , Ivermectina/administração & dosagem , Wuchereria bancrofti/efeitos dos fármacos , Animais , Esquema de Medicação , Quimioterapia Combinada , Filariose Linfática/tratamento farmacológico , Filariose Linfática/parasitologia , Humanos , Técnica de Amplificação ao Acaso de DNA Polimórfico , Wuchereria bancrofti/genéticaRESUMO
Lymphatic filarial (LF) parasites have been under anti-filarial drug pressure for more than half a century. Currently, annual mass drug administration (MDA) of diethylcarbamazine (DEC) or ivermectin in combination with albendazole (ALB) have been used globally to eliminate LF. Long-term chemotherapies exert significant pressure on the genetic structure of parasitic populations. We investigated the genetic variation among 210 Wuchereria bancrofti populations that were under three different chemotherapy strategies, namely MDA with DEC alone (group I, n = 74), MDA with DEC and ALB (group II, n = 60) and selective therapy (ST) with DEC (group III, n = 34) to understand the impact of these three drug regimens on the parasite genetic structure. Randomly amplified polymorphic DNA profiles were generated for the three groups of parasite populations; the gene diversity, gene flow and genetic distance values were determined and phylogenetic trees were constructed. Analysis of these parameters indicated that parasite populations under ST with a standard dose of DEC (group III) were genetically more diverse (0.2660) than parasite populations under MDA with DEC alone (group I, H = 0.2197) or with DEC + ALB (group II, H = 0.2317). These results indicate that the MDA may reduce the genetic diversity of W. bancrofti populations when compared to the genetic diversity of parasite populations under ST.